Clinical trial
Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or…
NCT00450944 · Albert Einstein College of Medicine, Other · Completed
Key facts
| NCT number | NCT00450944 |
|---|---|
| Title | Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia |
| Official title | A Phase I Study of Combination Therapy With Anti-CD19 and Anti-CD22 Immunotoxins (Combotox) in Adults With Refractory/Relapse Acute Lymphoblastic Leukemia |
| Lead sponsor | Albert Einstein College of Medicine, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological |
| Interventions | deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins |
| Enrollment | 10 |
| Start date | Feb 22, 2006 |
| Primary completion | Oct 27, 2008 |
| Completion | Apr 1, 2010 |
| First posted | Mar 22, 2007 |
| Last update posted | Apr 14, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: